The Public Health Vision Michael T. Osterholm, PhD, MPH Director, Center for Infectious Disease Research & Policy Director, Minnesota Center of Excellence.

Slides:



Advertisements
Similar presentations
Surveillance in a Pandemic: Situational Awareness
Advertisements

San Francisco Bay Area Advanced Practice Center. Who are we? San Francisco Bay Area Advanced Practice Center San Francisco Department of Public Health.
Delivering on the Promise of Data in Education Winter Forum February 2013 Jack Buckley Commissioner National Center for Education Statistics.
1 The Burden of Stroke in the Great Lakes States.
Challenges of the 2009 H1N1 Pandemic Influenza: Charles Penn Global Influenza Programme World Health Organization Geneva.
The Burden of Cancer and an Action Plan for Change in Monroe County January 2013 Byron Kennedy, MD, PhD, MPH Deputy Director of Health Monroe County, NY.
Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.
Project Immunize Virginia Diane Helentjaris, MD, MPH Director, Office of H1N1 Response Virginia Department of Health March 25, 2010 West Henrico Health.
U.S. Surveillance Update Anthony Fiore, MD, MPH CAPT, USPHS Influenza Division National Center for Immunizations and Respiratory Disease Centers for Disease.
Miriam Nuño Harvard School of Public Health, USA Gerardo Chowell Los Alamos National Laboratory, USA Abba Gumel University of Manitoba, Canada AIMS/DIMACS/SACEMA.
Statistics HAS Sources of knowing Tenacity Intuition Authority Personal experience Reasoning Deductive Inductive.
Pandemic Preparedness: Planning for Business Continuity, Productivity, and Resilience Rick Allen, PhD Peter Wald, MD, MPH September
Measuring the Aggregate Economy The government is very keen on amassing statistics... They collect them, add them, raise them to the n th power, take the.
Influenza Timothy Wiemken, PhD MPH CIC Assistant Professor Division of Infectious Diseases University of Louisville
Pandemic Influenza Preparedness Kentucky Department for Public Health Department for Public Health.
Felix I. Zemel, MPH DrPH Student Tufts University School of Medicine.
Ethics Conference on Asian Flu Pandemic Ethical considerations among Response to H1N1 Pandemic in China China CDC, CFETP Huilai Ma, Guang Zeng.
Influenza Surveillance at IRID Immunization and Respiratory Infections Division Centre for Infectious Disease Prevention & Control Public Health Agency.
Framework for Rebuilding Public Health Systems in Somalia Fozia Abrar, MD, MPH Department Head/Medical Director HealthPartners Occupational and Environmental.
Philadelphia Actuaries Club Pandemics – Past, Present and Future Presented by Annemarie Brownmiller Consulting Services of Princeton, LLC 19 November 2009.
Organization of the US Health Services System
TANEY COUNTY HEALTH DEPARTMENT AUGUST 2009 Situation Update: H1N1 Influenza A.
Immunization in the Time of H1N1 Anne Schuchat, MD Rear Admiral, US Public Health Service Director, National Center for Immunization and Respiratory Diseases.
Pandemic Influenza; A Harbinger of Things to Come Michael T Osterholm PhD, MPH Director, Center for Infectious Disease Research and Policy Associate Director,
Learning from the 2009 H1N1 Pandemic Response 1 Daniel S. Miller MD, MPH Director, International Influenza Unit Office of the Secretary Office of Global.
Stanislaus County It’s Not Flu as Usual It’s Not Flu as Usual Pandemic Influenza Preparedness Renee Cartier Emergency Preparedness Manager Health Services.
Flu Vaccine Locator: An Web Application to Increase Awareness and Access to Flu Vaccines Immunization Program Data Resources Program Utah Department of.
In healthy adults Naisi Zhao LIVE AEROSOL VACCINES.
The Impact of Racial and Ethnic Disparities in Influenza Vaccination on Minority Deaths Kevin Fiscella, MD, MPH Departments of Family Medicine Community.
CDC’s Preemie Act Activities Wanda Barfield, MD, MPH, FAAP Director, Division of Reproductive Health National Center for Chronic Disease Prevention and.
Asthma Disparities – A Focused Examination of Race and Ethnicity on the Health of Massachusetts Residents Jean Zotter, JD Director, Asthma Prevention and.
Influenza-like Illness Surveillance at the National Level
Surveillance Systems: Their Role in Identifying Risk and Resilience Factors Diego E Zavala, M.Sc., Ph.D. Associate Professor Public Health Program, Ponce.
Lessons from the European Experience with A(H1N1) 2009 Angus Nicoll CBE European Centre for Disease Prevention and Control 3 rd meeting of the National.
Influenza Mortality Surveillance… Making Real-Time National Mortality Surveillance a Reality National Center for Health Statistics Division of Vital Statistics.
2007 General Meeting Assemblée générale 2007 Montréal, Québec 2007 General Meeting Assemblée générale 2007 Montréal, Québec Canadian Institute of Actuaries.
Introduction: Thinking Like an Economist CHAPTER 7 Measuring the Aggregate Economy The government is very keen on amazing statistics…They collect them,
The Human Population and Its Impact
Food and Drug Administration
Chapter Two Measuring Offenses by and against Juveniles.
US Situation Update and CDC International Response H1N1 Pandemic US Situation Update and CDC International Response Peter Nsubuga, MD, MPH On behalf of.
U.S. Pandemic Influenza Preparedness and Response: Update & Progress Report “The pandemic influenza clock is ticking. We just don’t know what time it is.”
Calculation of excess influenza mortality for small geographic regions Al Ozonoff, Jacqueline Ashba, Paola Sebastiani Boston University School of Public.
1 Findings from Recent Consumer and Health-Care Provider Surveys Adelphi Research by Design supported by sanofi pasteur David R. Johnson, MD, MPHNVAC Meeting.
Influenza Nancy V. Rodway MD MPH MS Medical Director LakeHealth System Occupational Medicine and Urgent Care.
The Vermont Department of Health Overview of Pandemic Influenza Regional Pandemic Planning Summits 2006 Guidance Support Prevention Protection.
National Mortality Surveillance: Building a Foundation Paul D. Sutton, Ph.D. Mortality Surveillance Team Lead NAPHSIS/NCHS Joint Meeting Phoenix, Arizona.
William W. Thompson, PhD Immunization Safety Office Office of the Chief Science Officer Centers for Disease Control and Prevention Impact of Seasonal Influenza.
Virion Structure and Organization
NVAC Influenza Vaccine Recommendations and Strategies Subgroup Members: Jerome Klein (Chair), Jeff Davis, Jon Abramson, Carolyn Bridges, Nancy Cox, Ben.
Foodborne Campylobacteriosis in New Zealand Evidence rather than prejudice Donald Campbell Principal Advisor (Public Health) Science Group.
Module Science-Based Road Safety Research Describe and value science-based road safety research and its application as fundamental to achieving further.
Vaccines and Related Biological Products Advisory Committee Meeting July 23, 2009 Novel influenza A (H1N1) Epidemiology Update Anthony Fiore, MD, MPH Influenza.
U.S. Outpatient Influenza-Like Illness Surveillance Network (ILINet) Neil Pascoe for Irene Brown.
LIVING IN THE ENVIRONMENT 17 TH MILLER/SPOOLMAN Chapter 6 The Human Population and Its Impact.
NVAC Influenza Working Group Vaccine Research, Development and Production.
The Vermont Department of Health Update on Pandemic Threat Cort Lohff, MD, MPH State Epidemiologist Guidance Support Prevention Protection.
ESS Topic 3 Lesson 4 Key Concepts: Computer simulations, population projection. Assessment Statements
Vaccines for preventing influenza in healthy adults: a Cochrane review Clinical
Epidemiology: The Study of Disease, Injury, and Death in the Community Chapter 3.
CVD Testing the H1N1 Pandemic Flu Vaccines Mini-Med School Karen Kotloff, MD University of Maryland School of Medicine Center for Vaccine Development September.
Date of download: 6/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Impact of Influenza Vaccination on Seasonal Mortality.
National Immunization Conference March 9, 2006 Walter A. Orenstein, M.D. Professor of Medicine and Pediatrics Director, Emory Vaccine Policy and Development.
Introduction: Thinking Like an Economist 1 CHAPTER 2 Measuring the Aggregate Economy The government is very keen on amazing statistics…They collect them,
Epidemiology of influenza: is there a role for climate ?
SWİNE FLU AWARENESS OF PHYSİCİANS
2016 Tokelau Census of Population and Dwellings
Vaccine effectiveness – 2017/18
U.S. Influenza Sentinel Provider Surveillance Network
“Cost effectiveness analysis of school influenza vaccination program”
Presentation transcript:

The Public Health Vision Michael T. Osterholm, PhD, MPH Director, Center for Infectious Disease Research & Policy Director, Minnesota Center of Excellence for Influenza Research and Surveillance Professor, Division of Environmental Health Sciences, School of Public Health Adjunct Professor, Medical School University of Minnesota

The Public Health Vision Describing and understanding influenza pandemics Public health under attack Vaccines and tomorrow Modeling as a tool The next pandemic landfall

The Public Health Vision Describing and understanding influenza pandemics Public health under attack Vaccines and tomorrow Modeling as a tool The next pandemic landfall

Making Sense of Influenza Pandemics Assessment of the novel H1N1 pandemic and this meeting: –“We are fortunate that this was a mild pandemic.” –“If this virus had been deadly….” –“This pandemic was really just a dry run.” –“This pandemic was regarded as not severe.” –The 2009 pandemic….largely a huge relief and a practice run.” Our current “mild, moderate and severe” measurement system (i.e. number of deaths) is outdated Death is a difficult topic to discuss, particularly when it’s about ourselves

Viboud C, Miller M, Olson D, Osterholm M, Simonsen L. March 20,2010 Preliminary Estimates of Mortality and Years of Life Lost Associated With the 2009 A/H1N1 Pandemic In the US and Comparison With Past Influenza Seasons

Estimates of Number of Deaths, Mean Age of Deaths, and Years of Life Lost Attributable to the 2009 Pandemic In the US. Number of deaths (adjusted to 2000 pop.) Mean age of deaths (yrs) Years of life lost (adjusted to 2000 pop.) 2009 Pandemic 7,500-44,100 * ,000-1,973,000 12,000 (8, ) **463,300 (328,900 – 680,300) 1968 Pandemic86,000 ***62.21,693, Pandemic150,600 ***64.62,698, Pandemic1,272,300 ***27.263,718,000 Average A/H3N2 season, ,800 *** ,000 * Range is based on estimates of excess P&I deaths (lower) and all-cause deaths (upper), based on projections from the 122 cities mortality surveillance ** Estimates based on CDC’s probabilistic estimates, using 2009 pandemic survey data (different from CDC’s excess mortality method for measuring seasonal influenza burden) *** Estimates based on excess mortality approach applied to final national vital statistics and adjusted to the 2000 population age structure

Viboud C, Miller M, Olson D, Osterholm M, Simonsen L March 20 Death and Years of Life Lost From Influenza

Mean Age of Death for Influenza Pandemics and Life Expectancy At Birth; United States Life Mean Age of Year Expectancy Death Difference (29.2) (4.5) (8.1) (37.2)

Making Sense of Influenza Pandemics The 2009 novel H1N1 influenza pandemic, together with the experience of the 3 previous pandemics, seasonal influenza and H5N1, reinforces that “flu isn’t simple” Our current “mild, moderate and severe” measurement system (i.e. number of deaths) is outdated We need a new way to measure and describe the impact of pandemic influenza in a modern world –years of life lost –impact on our modern health care system –impact on the “just-in-time” global economy

The Public Health Vision Describing and understanding influenza pandemics Public health under attack Vaccines and tomorrow Modeling as a tool The next pandemic landfall

The Anti-Science Movement “Anti-science, in modern terms, refers to largely ideological attacks on the teaching of evolutionary theory, global climate change, various sorts of medical and public health measures and other sciences. This is particularly true when there is conflict with political or religious pseudo-scientific positions.” The anti-science position generally holds that in cases where science and ideology come into conflict, science itself must be flawed. Anti-science based efforts are often well orchestrated and well financed. They also focus on attacking both the science and individual researchers, practitioners and policy leaders.

The Public Health Vision Describing and understanding influenza pandemics Public health under attack Vaccines and tomorrow Modeling as a tool The next pandemic landfall

Vaccines and Tomorrow Efficacy and effectiveness Availability Safety Role of adjuvants

Vaccines and Tomorrow Efficacy and effectiveness Availability Safety Role of adjuvants

Current Whole, Split and Live Virus Seasonal Influenza Vaccines Efficacy/effectiveness in the elderly –Only one randomized control trial in 40 years that has adequate follow up and case definition criteria, randomization, allocation concealment and addresses selection bias (927 treated, 911 controls) –VE=59% (26-77%) Efficacy/effectiveness in everybody else –VE=0 to 80% and varies by antigen match, age and underlying health conditions The public has limited understanding of the relative lack of influenza vaccine efficacy/effectiveness compared to other immunizations

Vaccines For Preventing Influenza In The Elderly Cochrane Review, 2010 Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE “The available evidence is of poor quality and provides no guidance regarding the safety, efficacy or effectiveness of influenza vaccines for people aged 65 years or older. To resolve the uncertainty, an adequately powered publicly- funded randomised, placebo-controlled trial run over several seasons should be undertaken.”

Vaccines and Tomorrow Efficacy and effectiveness Availability Safety Role of adjuvants

Source: CDC ILI and Vaccine Distribution Data Percentage of Visits for ILI and H1N1 Vaccine Distribution, Sept 2009 – May 2010

Vaccines and Tomorrow Efficacy and effectiveness Availability Safety Role of adjuvants

Vaccines and Tomorrow Efficacy and effectiveness Availability Safety Role of adjuvants

Vaccines and Tomorrow The influenza research and public health communities must confront the issue of the relative lack of efficacy/effectiveness of our current whole, spilt and live attenuated influenza vaccines We have an urgent need to change our “gradual migration approach” from a 1950s-based influenza vaccine technology to 21 st century universal-based vaccines; we need a game-changer approach The anti-science movement is already seizing on this issue; we owe it to the world to address it head on!

The Public Health Vision Describing and understanding influenza pandemics Public health under attack Vaccines and tomorrow Modeling as a tool The next pandemic landfall

“The Government are very keen on amassing statistics - they collect them, add them, raise them to the nth power, take the cube root and prepare wonderful diagrams. But you must never forget that every one of these figures comes in the first instance from the village watchman, who just puts down what he damn pleases.” Sir Josiah Stamp

The Public Health Vision Describing and understanding influenza pandemics Public health under attack Vaccines and tomorrow Modeling as a tool The next pandemic landfall

Pandemic Arrival Timeline (Years) ???

The Public Health Vision Describing and understanding influenza pandemics Public health under attack Vaccines and tomorrow Modeling as a tool The next pandemic landfall

“It’s no use saying, ‘We’re doing our best.’ You have got to succeed in doing what is necessary.” Sir Winston Churchill